5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

Annals of Oncology ◽

10.1093/annonc/mdz100.001 ◽

2019 ◽

Vol 30 ◽

pp. iii47 ◽

Cited By ~ 2

Author(s):

J. Huober ◽

K. Ribi ◽

P. Weder ◽

Q. Li ◽

L. Vanlemmens ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)

Annals of Oncology ◽

10.1093/annonc/mdy272.280 ◽

2018 ◽

Vol 29 ◽

pp. viii93 ◽

Cited By ~ 4

Author(s):

J. Huober ◽

P. Weder ◽

C. Veyret ◽

B. Thürlimann ◽

A. Xyrafas ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.309 ◽

2018 ◽

Vol 29 ◽

pp. viii102

Author(s):

P. Krivorotko ◽

B. Karaszewska ◽

S. Chan ◽

M. Wieczorek-Rutkowska ◽

T. Sarosiek ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps120 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS120-TPS120

Author(s):

H. L. Gomez ◽

S. P. Neciosup ◽

Y. Neron do Nascimento ◽

G. Ismael ◽

C. H. Barrios

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)

Open Access Journal of Clinical Trials ◽

10.2147/oajct.s155706 ◽

2018 ◽

Vol Volume 10 ◽

pp. 13-18

Author(s):

Tatsunori Shimoi ◽

Akihiko Shimomura ◽

Tadahiko Shien ◽

Yukari Uemura ◽

Hiroaki Kato ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

Open Label Phase ◽

Er Positive

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

Breast Cancer Research ◽

10.1186/bcr3661 ◽

2014 ◽

Vol 16 (3) ◽

Cited By ~ 30

Author(s):

Edith A Perez ◽

Sara A Hurvitz ◽

Lukas C Amler ◽

Kirsten E Mundt ◽

Vivian Ng ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Expression ◽

First Line ◽

Her2 Positive ◽

Randomized Phase Ii

P1-12-02: Patient-Reported Outcomes (PROs) from a Randomized Phase II Study (TDM4450g/BO21976) of Trastuzumab Emtansine (T-DM1) vs Trastuzumab Plus Docetaxel (HT) in Previously Untreated HER2−Positive Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs11-p1-12-02 ◽

2011 ◽

Cited By ~ 2

Author(s):

GV Bianchi ◽

J Kocsis ◽

L Dirix ◽

Y Torigoe ◽

D Lalla ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Patient Reported

5067 Increased overall response rate to capecitabine in different patient subgroups: results of an open-label phase II study in pretreated metastatic breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70959-0 ◽

2009 ◽

Vol 7 (2) ◽

pp. 280

Author(s):

P. Reichardt ◽

G. von Minckwitz ◽

P. Thuss-Patience

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Overall Response Rate ◽

Response Rate ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

Open Label Phase ◽

Patient Subgroups

Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2- metastatic breast cancer (Chloe trial)

Annals of Oncology ◽

10.1093/annonc/mdx365.076 ◽

2017 ◽

Vol 28 ◽

pp. v104

Author(s):

T. Shien ◽

A. Shimomura ◽

Y. Uemura ◽

H. Kato ◽

M. Kitada ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

Menopausal Women ◽

Open Label Phase ◽

Post Menopausal

Abstract OT3-01-04: An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for the treatment of central nervous system progression post-radiotherapy in patients with HER2-positive metastatic breast cancer (PATRICIA)

10.1158/1538-7445.sabcs15-ot3-01-04 ◽

2016 ◽

Author(s):

NU Lin ◽

MD Pegram ◽

C Lai ◽

A Lacasia ◽

A Stein ◽

...

Keyword(s):

Breast Cancer ◽

Central Nervous System ◽

Nervous System ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

High Dose ◽

Her2 Positive ◽

Open Label